

Special Issue

Epigenetic Modifications as Biomarkers of Tumor Development

Message from the Guest Editor

Understanding of epigenomics revolutionizes the way of screening, diagnosing and treating cancers. Unlike static genetic mutations, epigenetic alterations, including DNA methylation, histone modifications and non-coding RNA dysregulation, offer a dynamic and potentially reversible biomarker of oncogenesis. This Special Issue aims to bridge the gap between basic molecular research and clinical application. We invite original research and comprehensive reviews that explore the identification, validation and implementation of epigenetic signatures as robust biomarkers for cancer screening, early diagnosis and monitoring. By focusing on early detection, therapeutic monitoring and the prediction of treatment response, this collection seeks to highlight how the epigenetics can redefine diagnostic accuracy and patient outcomes in modern cancer care.

Guest Editor

Dr. Chenkai Ma

Commonwealth Scientific and Industrial Research Organisation (CSIRO), Canberra, ACT 2601, Australia

Deadline for manuscript submissions

31 October 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/274138

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)